Recent Updates
Recently added Catalysts
AGMB Positive Sentiment

Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

Tuesday, October 10, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agomab Therapeutics NV has successfully closed a $100 million Series C financing round. The funding was led by Fidelity Management & Research Company and included participation from new investors such as EQT Life Sciences and Canaan. This capital will be utilized to advance Agomab's pipeline focused on fibrosis.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agomab secured $100 million in Series C financing.
  • The funding will support their fibrosis-focused pipeline.
  • Participation from reputable investors indicates strong confidence.

Full Press Release Details

– Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.

Frequently Asked Questions

What is the amount raised in Agomab's Series C financing?

Agomab raised $100 million in its Series C financing round.

Who led the Series C financing for Agomab?

The financing round was led by Fidelity Management & Research Company.

What will the funding be used for?

The funds will be used to advance Agomab's fibrosis-focused pipeline.

Which investors participated in Agomab's financing round?

New investors included EQT Life Sciences and Canaan, among others.

ShareAdd on Google
Tags: AGMB Viatris Investor Conferences Healthcare Agomab fibrosis Series C Fidelity Management EQT Life Sciences
Last updated: Oct 10, 2023

Biotech snapshot

Lead asset
AGMB-129Phase 2
Fibrostenotic Crohn's Disease →